Amphastar Pharmaceuticals Inc. logo

Amphastar Pharmaceuticals Inc. (AMPH)

Market Closed
17 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
19. 75
-0.11
-0.5539%
$
829.17M Market Cap
- P/E Ratio
- Div Yield
338,500 Volume
- Eps
$ 19.86
Previous Close
Add Transaction
Day Range
19.63 20.35
Year Range
16.65 31.26
Want to track AMPH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

AMPH closed yesterday lower at $19.75, a decrease of -0.5539% from Thursday's close, completing a monthly increase of 6.0118% or $1.12. Over the past 12 months, AMPH stock lost -26.6072%.
AMPH is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.3217%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

AMPH Chart

People also search for

GT
The Goodyear Tire & Rubber Company
$ 7.29
+2.6761%
Interface Inc.
$ 33.06
-2.7361%
Strategic Education Inc.
$ 76.53
-1.4931%
Lincoln Educational Services Corporation
$ 42.95
-2.5414%
EYE
National Vision Holdings Inc.
$ 20.73
-0.3365%
New Strong Sell Stocks for June 23rd

New Strong Sell Stocks for June 23rd

ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.

Zacks | 3 weeks ago
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth

Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth

Amphastar Pharmaceuticals NASDAQ: AMPH is positioning itself for a broader shift from complex generics toward proprietary medicines and biosimilars, Chief Financial Officer and Executive Vice President of Finance Bill Peters told investors at the East Coast IDEAS Conference.

Marketbeat | 1 month ago
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag

Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag

Amphastar Pharmaceuticals NASDAQ: AMPH executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in 2026, supported by a new generic launch, Primatene Mist growth and selected API sales from its China business.

Marketbeat | 1 month ago

Amphastar Pharmaceuticals Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
CE
Curtis Ellergodt Rothschild Investment LLC
25 $612.37 $481.86 -$130.51 -21.31%
SN
Stephanie Nee HARBOR CAPITAL ADVISORS Inc.
391 $9,948.52 $7,563.89 -$2,384.63 -23.97%
BG
Bart Gancher Intech Investment Management LLC
24,207 $674,873.55 $468,163.38 -$206,710.17 -30.63%
YA
Yinka Akinsola Blue Trust Inc.
1,607 $53,998.85 $31,047.24 -$22,951.61 -42.5%
Jeff Ameen
Jeff Ameen Spire Wealth Management
206 $8,063.15 $3,873.83 -$4,189.32 -51.96%

Amphastar Pharmaceuticals Inc. (AMPH) FAQ

What is the stock price today?

The current price is $19.75.

On which exchange is it traded?

Amphastar Pharmaceuticals Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is AMPH.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 829.17M.

Has Amphastar Pharmaceuticals Inc. ever had a stock split?

No, there has never been a stock split.

Amphastar Pharmaceuticals Inc. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Yongfeng Zhang CEO
NASDAQ (NGS) Exchange
03209R103 CUSIP
US Country
1,976 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company that focuses on the development, manufacturing, marketing, and sale of both generic and proprietary injectable, inhalation, and intranasal products. The company has a global footprint with operations in the United States, China, and France. Established in 1996 and based in Rancho Cucamonga, California, Amphastar Pharmaceuticals caters to a diverse range of medical needs, emphasizing solutions for severe hypoglycemia, opioid overdose, adrenocortical insufficiency, intermittent asthma, and deep vein thrombosis among others. Additionally, the company engages in the distribution of insulin APIs and is involved in the development of generic, biosimilar, and innovative analytical technologies.

Products and Services

  • BAQSIMI - A nasal spray designed for severe hypoglycemia treatment.
  • Primatene Mist - An over-the-counter epinephrine inhalation product for mild asthma symptoms.
  • Enoxaparin - Used to prevent and treat deep vein thrombosis.
  • REXTOVY and Naloxone - Intended for the reversal of opioid overdose.
  • Glucagon Emergency Kit - A kit for injection in emergency situations to treat hypoglycemia.
  • Cortrosyn - A diagnostic agent used in screening for adrenocortical insufficiency.
  • Amphadase - An injection that aids the absorption and dispersion of other injected drugs.
  • Epinephrine Injection - For the management of allergic reactions.
  • Lidocaine Jelly and Topical Solution - Anesthetics for urological and various other procedures.
  • Phytonadione Injection - A vitamin K1 injection for newborns.
  • Emergency Syringe Products - Various products designed for emergency medical use.
  • Morphine Injection - For use with patient-controlled analgesia pumps.
  • Lorazepam Injection - Used for anxiety relief during surgery and medical procedures.
  • Neostigmine Methylsulfate Injection - Treats myasthenia gravis and reverses the effects of muscle relaxants.
  • Isoproterenol Hydrochloride Injection - Manages mild or transient episodes of heart block.
  • Ganirelix Acetate Injection - Used for the inhibition of premature luteinizing hormone surges.
  • Vasopressin - Administered to increase blood pressure in vasodilatory shock.
  • Regadenoson - A stress agent used in radionuclide myocardial perfusion imaging.
  • Insulin API Distribution - Distributes recombinant human and porcine insulin APIs.
  • Generic Product Candidates - Focuses on developing injectable, inhalation, and analytical technologies.
  • Biosimilar Product Candidates - Develops alternatives to existing biologic medicines.
  • Intranasal Epinephrine - Under development for treating allergic reactions.

Contact Information

Address: 11570 6th Street
Phone: 909 980 9484